Figure 3

The outcomes of patients who developed therapy-related myeloid neoplasms after FCR treatment. Patient survival was estimated by the Kaplan–Meier curve from the date of therapy-related myeloid neoplasms diagnosis until death attributed to therapy-related myeloid neoplasms. The median survival was 7 months.